H.C. Wainwright Remains Bullish on Immunocore Holdings plc (IMCR)

Immunocore Holdings plc (NASDAQ:IMCR) is one of the best small cap stocks with the highest upside. Immunocore Holdings plc (NASDAQ:IMCR) received a rating update from H.C. Wainwright analyst Patrick Trucchio on October 15, who assigned the stock a Buy rating with a price target of $100.

Additionally, Immunocore Holdings plc (NASDAQ:IMCR) was initiated with a Neutral rating by Guggenheim on September 17. The firm told investors in a research note that Immunocore Holdings plc (NASDAQ:IMCR) is a pioneer of the TCR therapeutics domain and has a strong commercial foundation in Kimmtrak, which is the only FDA-approved systemic therapy for metastatic uveal melanoma.

The drug has consistently surpassed Wall Street expectations since its launch in 2022, the firm added. However, it also stated that it sees fewer means of commercial outperformance for the drug in the next leg of growth, contributing to the neutral rating.

Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that develops a novel class of TCR bispecific immunotherapies called ImmTAX (Immune mobilizing monoclonal TCRs Against X disease). The company’s lead product is KIMMTRAK, which is a TCR therapeutic to treat patients with unresectable or metastatic uveal melanoma, in the United Kingdom, the United States, the European Union, Canada, and Australia. Immunocore Holdings plc’s (NASDAQ:IMCR) product pipeline includes IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others.

While we acknowledge the potential of IMCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.